The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies
| Autor: | Andrew J. Murphy, Hilary M. Staples, George D. Yancopoulos, Kristen E. Pascal, Yi Wei, Kathryn Lanza, Sumathi Sivapalasingam, Shane McCarthy, Angel Coppola, Selin Somersan-Karakaya, Matthew C. Franklin, Sara Hamon, David M. Weinreich, Yi Zhou, Alina Baum, Thomas Norton, Gurinder S. Atwal, Kendra J. Alfson, Andrea T. Hooper, Elzbieta Wloga, Kei Saotome, Gary Herman, Stephanie Giordano, Benjamin O. Fulton, Newton Chan, Shazia Ali, Min Ni, Leah Lipsich, Nicole Negron, Anbo Zhou, Annabel Romero Hernandez, Richard Copin, Christos A. Kyratsous, Ricardo Carrion, Joyce Chiu, Neil Stahl, Jennifer D. Hamilton |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Male
medicine.drug_class viruses Population Hamster medicine.disease_cause Monoclonal antibody Article General Biochemistry Genetics and Molecular Biology Virus 03 medical and health sciences 0302 clinical medicine Neutralization Tests Cricetinae Chlorocebus aethiops medicine Animals Humans education Lung Vero Cells 030304 developmental biology 0303 health sciences Mutation education.field_of_study biology SARS-CoV-2 Cryoelectron Microscopy Antibodies Monoclonal COVID-19 Viral Load Virology Hospitalization biology.protein Vero cell Antibody Viral load 030217 neurology & neurosurgery |
| Zdroj: | Cell |
| ISSN: | 0092-8674 |
| Popis: | Monoclonal antibodies against SARS-CoV-2 are a clinically validated therapeutic option against COVID-19. As rapidly emerging virus mutants are becoming the next major concern in the fight against the global pandemic, it is imperative that these therapeutic treatments provide coverage against circulating variants and do not contribute to development of treatment-induced emergent resistance. To this end, we investigated the sequence diversity of the spike protein and monitored emergence of virus variants in SARS-COV-2 isolates found in COVID-19 patients treated with the two-antibody combination REGEN-COV, as well as in preclinical in vitro studies using single, dual, or triple antibody combinations, and in hamster in vivo studies using REGEN-COV or single monoclonal antibody treatments. Our study demonstrates that the combination of non-competing antibodies in REGEN-COV provides protection against all current SARS-CoV-2 variants of concern/interest and also protects against emergence of new variants and their potential seeding into the population in a clinical setting. Treatment with monoclonal antibody combinations limits generation of SARS-CoV-2 escape variants in humans and model animals, and protects against current variants of concern. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|